Bereich
Brustzentrum St.Gallen
BZ · Dept. IV
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98
Viale G, Gusterson B, Goldhirsch A, Price K, Castiglione-Gertsch M, Gelber R, Thürlimann B, Öhlschlegel C, Braye S, Orosz Z, Neven P, Raffoul J, Rasmussen B, Dell'Orto P, Mastropasqua M, Maiorano E, Regan M, Coates A. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007; 25:3846-52.
06.08.2007Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98
06.08.2007J Clin Oncol 2007; 25:3846-52
Viale Giuseppe, Gusterson Barry A, Goldhirsch Aron, Price Karen N, Castiglione-Gertsch Monica, Gelber Richard D, Thürlimann Beat, Öhlschlegel Christian, Braye Stephen, Orosz Zsolt, Neven Patrick, Raffoul Johnny, Rasmussen Birgitte Bruun, Dell'Orto Patrizia, Mastropasqua Mauro G, Maiorano Eugenio, Regan Meredith M, Coates Alan S
Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer
Klaeser B, Wiederkehr O, Köberle D, Mueller A, Bubeck B, Thürlimann B. Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer. Ann Oncol 2007; 18:1329-34.
01.08.2007Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer
01.08.2007Ann Oncol 2007; 18:1329-34
Klaeser B, Wiederkehr O, Köberle Dieter, Mueller A, Bubeck B, Thürlimann Beat
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007
Goldhirsch A, Wood W, Gelber R, Coates A, Thürlimann B, Senn H, 10th St. Gallen conference. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18:1133-44.
01.07.2007Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007
01.07.2007Ann Oncol 2007; 18:1133-44
Goldhirsch A, Wood W C, Gelber R D, Coates A S, Thürlimann Beat, Senn H-J, 10th St. Gallen conference
Combining chemotherapy and low-molecular-weight heparin for the treatment of advanced breast cancer: results on clinical response, transforming growth factor-beta 1 and fibrin monomer in a phase II study
Seeholzer N, Thürlimann B, Köberle D, Hess D, Korte W. Combining chemotherapy and low-molecular-weight heparin for the treatment of advanced breast cancer: results on clinical response, transforming growth factor-beta 1 and fibrin monomer in a phase II study. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2007; 18:415-23.
01.07.2007Combining chemotherapy and low-molecular-weight heparin for the treatment of advanced breast cancer: results on clinical response, transforming growth factor-beta 1 and fibrin monomer in a phase II study
01.07.2007Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2007; 18:415-23
Seeholzer Niels, Thürlimann Beat, Köberle Dieter, Hess Dagmar, Korte Wolfgang
123I-Methyljodbenzylguanidin- (MIBG-) Szintigraphie: Paradoxe Nuklidspeicherung eines onkozytären Nebennierenrindenkarzinoms.
Padberg B, Rordorf T, Suter S, Pfeiffer D, Wild D, Schröder S. 123I-Methyljodbenzylguanidin- (MIBG-) Szintigraphie: Paradoxe Nuklidspeicherung eines onkozytären Nebennierenrindenkarzinoms. Pathologe 2007; 28:281-4.
01.07.2007123I-Methyljodbenzylguanidin- (MIBG-) Szintigraphie: Paradoxe Nuklidspeicherung eines onkozytären Nebennierenrindenkarzinoms.
01.07.2007Pathologe 2007; 28:281-4
Padberg B-C, Rordorf Tamara, Suter S, Pfeiffer D, Wild D, Schröder Stephan
Riniker S, Köberle D. (Neo-) Adjuvante Therapien des Rektumkarzinoms: Neue Strategien
Riniker S. Riniker S, Köberle D. (Neo-) Adjuvante Therapien des Rektumkarzinoms: Neue Strategien. Schweizer Zeitschrift für Onkologie 2007; 3:25-28.
29.06.2007Riniker S, Köberle D. (Neo-) Adjuvante Therapien des Rektumkarzinoms: Neue Strategien
29.06.2007Schweizer Zeitschrift für Onkologie 2007; 3:25-28
Riniker Salome
Intra-operative sonography: a valuable aid during breast-conserving surgery for occult breast cancer
Haid A, Wenzl E, Haid B, Toeppker M, Schuster A, Köberle-Wührer R, Jasarevic Z, Dunzinger S, Knauer M, Offner F. Intra-operative sonography: a valuable aid during breast-conserving surgery for occult breast cancer. Ann Surg Oncol 2007; 14:3090-101.
26.06.2007Intra-operative sonography: a valuable aid during breast-conserving surgery for occult breast cancer
26.06.2007Ann Surg Oncol 2007; 14:3090-101
Haid Anton, Wenzl Etienne, Haid Bernhard, Toeppker Michael, Schuster Antonius, Köberle-Wührer Roswitha, Jasarevic Zerina, Dunzinger Stephanie, Knauer Michael, Offner Felix
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
Herrmann R, Stemmer S, Tàmas K, Kornek G, Köberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W, Swiss Group for Clinical Cancer Research, Mingrone W, Köhne C, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Central European Cooperative Oncology Group. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007; 25:2212-7.
01.06.2007Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
01.06.2007Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007; 25:2212-7
Herrmann Richard, Stemmer Salomon M, Tàmas Karin, Kornek Gabriela V, Köberle Dieter, Cina Susanne, Bernhard Jürg, Dietrich Daniel, Scheithauer Werner, Swiss Group for Clinical Cancer Research, Mingrone Walter, Köhne Claus-Henning, Bodoky György, Ruhstaller Thomas, Glimelius Bengt, Bajetta Emilio, Schüller Johannes, Saletti Piercarlo, Bauer Jean, Figer Arie, Pestalozzi Bernhard, Central European Cooperative Oncology Group
The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer
Karlsson P, Goldhirsch A, Gelber R, Forbes J, Crivellari D, Thürlimann B, Fey M, Holmberg S, Collins J, Lindtner J, Murray E, Gusterson B, Castiglione-Gertsch M, Coates A, Price K, Cole B, Wallgren A. The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer. JCO 2007; 25:2019-26.
20.05.2007The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer
20.05.2007JCO 2007; 25:2019-26
Karlsson Per, Goldhirsch Aron, Gelber Richard D, Forbes John F, Crivellari Diana, Thürlimann Beat, Fey Martin F, Holmberg Stig B, Collins John P, Lindtner Jurij, Murray Elizabeth, Gusterson Barry A, Castiglione-Gertsch Monica, Coates Alan S, Price Karen N, Cole Bernard F, Wallgren Arne
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
Mauriac L, Castiglione-Gertsch M, Price K, Coates A, Smith I, Viale G, Rabaglio M, Zabaznyi N, Goldhirsch A, BIG 1-98 Collaborative Group, Gelber R, Nogaret J, Keshaviah A, Debled M, Mouridsen H, Forbes J, Thürlimann B, Paridaens R, Monnier A, Láng I, Wardley A, International Breast Cancer Study Group. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 2007; 18:859-67.
01.05.2007Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
01.05.2007Ann Oncol 2007; 18:859-67
Mauriac L, Castiglione-Gertsch M, Price K N, Coates A S, Smith I, Viale G, Rabaglio M, Zabaznyi N, Goldhirsch A, BIG 1-98 Collaborative Group, Gelber R D, Nogaret J-M, Keshaviah A, Debled M, Mouridsen H, Forbes J F, Thürlimann Beat, Paridaens R, Monnier A, Láng I, Wardley A, International Breast Cancer Study Group
CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials
Keshaviah A, Coates A, Gelber R, Castiglione Gertsch M, Simoncini E, Pagani O, Price K, Aebi S, Mendiola C, Thürlimann B, Colleoni M, Collins J, Crivellari D, Lindtner J, Rotmensz N, Dellapasqua S, Goldhirsch A. CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Ann Oncol 2007; 18:701-8.
01.04.2007CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials
01.04.2007Ann Oncol 2007; 18:701-8
Keshaviah A, Coates A S, Gelber R D, Castiglione Gertsch M, Simoncini E, Pagani O, Price K N, Aebi S, Mendiola C, Thürlimann Beat, Colleoni M, Collins J, Crivellari D, Lindtner J, Rotmensz N, Dellapasqua S, Goldhirsch A
Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study
Rupp U, Sohn C, Sinn H, Huober J, Hanft G, Staab A, Schmidt P, Lauschner I, Schuetz F, Eichbaum M, Schoendorf-Holland E, Schneeweiss A. Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study. Anti-cancer drugs 2007; 18:477-85.
01.04.2007Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study
01.04.2007Anti-cancer drugs 2007; 18:477-85
Rupp Ute, Sohn Christof, Sinn Hans-Peter, Huober Jens, Hanft Gertraud, Staab Alexander, Schmidt Peter, Lauschner Ilka, Schuetz Florian, Eichbaum Michael, Schoendorf-Holland Eva, Schneeweiss Andreas
Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)
Wagner U, Jackisch C, Meier W, Schmalfeldt B, Stähle A, Gropp M, Sehouli J, Lück H, Loibl S, Huober J, Pfisterer J, du Bois A, AGO Ovarian Cancer Study Group. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecologic oncology 2007; 105:132-7.
01.04.2007Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)
01.04.2007Gynecologic oncology 2007; 105:132-7
Wagner Uwe, Jackisch Christian, Meier Werner, Schmalfeldt Barbara, Stähle Anne, Gropp Martina, Sehouli Jalid, Lück Hans-Joachim, Loibl Sybille, Huober Jens, Pfisterer Jacobus, du Bois Andreas, AGO Ovarian Cancer Study Group
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98
Coates A, Del Mastro L, Smith I, Chirgwin J, Nogaret J, Pienkowski T, Wardley A, Jakobsen E, Price K, Láng I, Colleoni M, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes J, Paridaens R, Castiglione-Gertsch M, Gelber R, Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. JCO 2007; 25:486-92.
10.02.2007Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98
10.02.2007JCO 2007; 25:486-92
Coates Alan S, Del Mastro Lucia, Smith Ian, Chirgwin Jacquie, Nogaret Jean-Marie, Pienkowski Tadeusz, Wardley Andrew, Jakobsen Erik H, Price Karen N, Láng István, Colleoni Marco, Keshaviah Aparna, Thürlimann Beat, Mouridsen Henning, Mauriac Louis, Forbes John F, Paridaens Robert, Castiglione-Gertsch Monica, Gelber Richard D, Goldhirsch Aron
Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII
Bernhard J, Coates A, Goldhirsch A, Price K, Thürlimann B, Aebi S, Collins J, Murray E, Forbes J, Gelber R, Hürny C, Castiglione-Gertsch M, Zahrieh D, International Breast Cancer Study Group Trial VIII. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII. JCO 2007; 25:263-70.
20.01.2007Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII
20.01.2007JCO 2007; 25:263-70
Bernhard Jürg, Coates Alan S, Goldhirsch Aron, Price Karen N, Thürlimann Beat, Aebi Stefan, Collins John, Murray Elizabeth, Forbes John F, Gelber Richard D, Hürny Christoph, Castiglione-Gertsch Monica, Zahrieh David, International Breast Cancer Study Group Trial VIII
Pegylated liposomal doxorubicin (caelyx) in metastatic breast cancer: a community-based observation study
Salzberg M, Thürlimann B, Hasler U, Delmore G, von Rohr A, Thurlimann A, Ruhstaller T, Stopatschinskaja S, von Moos R. Pegylated liposomal doxorubicin (caelyx) in metastatic breast cancer: a community-based observation study. Oncology 2007; 72:147-51.
01.01.2007Pegylated liposomal doxorubicin (caelyx) in metastatic breast cancer: a community-based observation study
01.01.2007Oncology 2007; 72:147-51
Salzberg Marc, Thürlimann Beat, Hasler Ursula, Delmore Geoffrey, von Rohr Albert, Thurlimann Annatina, Ruhstaller Thomas, Stopatschinskaja Shanna, von Moos Roger
Das Ösophagus-Karzinom: Eine Krankheit mit vielen Variablen
Ruhstaller T. Das Ösophagus-Karzinom: Eine Krankheit mit vielen Variablen. Leading Opinions 2007; 5:8-11.
01.01.2007Das Ösophagus-Karzinom: Eine Krankheit mit vielen Variablen
01.01.2007Leading Opinions 2007; 5:8-11
Ruhstaller Thomas
Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99)
Hess D, Ribi K, Ballabeni P, Schuller J, Rauch D, Rochlitz C, Mattmann S, Schonenberger A, Pagani O, Thürlimann B, Köberle D, Swiss Group for Clinical Cancer Research. Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99). Oncology 2007; 73:228-37.
01.01.2007Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99)
01.01.2007Oncology 2007; 73:228-37
Hess Dagmar, Ribi K, Ballabeni P, Schuller J C, Rauch D, Rochlitz C, Mattmann S, Schonenberger A, Pagani O, Thürlimann Beat, Köberle Dieter, Swiss Group for Clinical Cancer Research
Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)
Perey L, Goldhirsch A, Köberle D, Clément P, Dietrich D, Fiche M, Wildiers H, Nolé F, Zaman K, Hawle H, Paridaens R, Thürlimann B. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol 2007; 18:64-9.
01.01.2007Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)
01.01.2007Ann Oncol 2007; 18:64-9
Perey L, Goldhirsch A, Köberle Dieter, Clément P, Dietrich D, Fiche M, Wildiers H, Nolé F, Zaman K, Hawle H, Paridaens R, Thürlimann Beat
Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98
Köberle D, Thürlimann B. Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98. Breast Cancer Res Treat 2007; 105 Suppl 1:55-66.
01.01.2007Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98
01.01.2007Breast Cancer Res Treat 2007; 105 Suppl 1:55-66
Köberle Dieter, Thürlimann Beat